(Denver, October 26, 2023) – The International Association for the Study of Lung Cancer has named Jennifer C. King, PhD, as its new Chief Science Officer. In this position, Dr. King will guide and implement the scientific strategy of the IASLC, support scientific research projects, and manage the Scientific Affairs department.
“Dr. King brings a complementary dimension to our scientific affairs team that emphasizes the IASLC’s commitment to science and patient benefit,” Dr. Karen Kelly, CEO of the IASLC said.
Dr. King received her Ph.D. in Biology from the Massachusetts Institute of Technology and a Bachelor of Science degree from Duke University. Dr. King studied new molecular targets for cancer therapeutics while working at Memorial Sloan Kettering Cancer Center and the Jonsson Comprehensive Cancer Center at UCLA. She has overseen research programs and portfolios at the American Society of Clinical Oncology, led data governance for real-world evidence utilization via new health information technology for CancerLinQ, and co-founded the patient-facing health data-sharing nonprofit, SHARE For Cures. Most recently, Dr. King served as the Chief Scientific Officer for GO2 for Lung Cancer, where she planned and executed new strategic initiatives to increase lung cancer survivorship.
In addition to her work in oncology, Dr. King is the President and Founder of Dysgraphia Life, an organization devoted to improving outcomes for people with specific learning disabilities in written expression. She founded Dysgraphia Life to raise awareness of dysgraphia while providing information, support, and resources to those with writing difficulties and their loved ones. Through that organization, she is the principal investigator of a PCORI-funded Engagement Award and has co-authored a book on learning goals for dysgraphia.
She is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the Learning Disabilities Association of America.
“I'm excited to join a science-forward organization where we can make a significant impact to conquer lung and other thoracic cancers worldwide in this century. I look forward to working with the IASLC team and the entire lung cancer community as we enhance collaborative science as part of the new strategic plan,” she said.
About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.